News
Why Revance Therapeutics Is Soaring Today
In response to the company's strong results from two pivotal phase 3 trials, shares of Revance Therapeutics (NASDAQ: RVNC), a clinical-stage biotech focused on aesthetics, rose 36% as of 11:10....
MorphoSys: Partner erhält Medikamenten-Zulassung in Kanada
Der MorphoSys-Lizenzpartner Janssen hat in Kanada die Zulassung zur Behandlung erwachsener Patienten mit moderater bis schwerer Form von Schuppenflechte mit dem Medikament Tremfya erhalten. Das....
Why Nektar Therapeutics Shares Delivered a Stupendous 124% in November
After the company updated the timeline for filing its pain-relieving drug for approval from the Food and Drug Administration, and presented early-stage study results for its solid-tumor cancer....
Why Ra Pharmaceuticals, Inc. Got Hammered Today
Ra Pharmaceuticals (NASDAQ: RARX) characterized its interim phase 2 data testing RA101495 SC in patients with paroxysmal nocturnal hemoglobinuria (PNH) as "positive," but the market sees it....
Why Endocyte, Inc. Stock Briefly Spiked Today
Shares of the clinical-stage biotech Endocyte (NASDAQ: ECYT) briefly rose by as much as 16% Monday on more than double the average daily volume. The catalyst? Investors appear to have noticed a....
1 High-Risk Penny Stock That May Be Worth Buying
Penny stocks, or stocks with a sub-$5 share price, generally aren't my cup of tea. These types of companies tend to be far too risky to make them worthy of serious investment consideration. The....
3 Stocks That Quadrupled
The stock market continues to put on a clinic about how to stomp all over expectations. The Dow Jones Industrial Average is up 25% this year and the S&P 500 is 20% higher, but stack them up....
Where Will Exact Sciences Corporation Be in 5 Years?
Roughly 18 months ago, Exact Sciences (NASDAQ: EXAS) was in rough shape. Cash was getting tight as the company spent aggressively to commercialize its new colon cancer test. Add in some troubling....
3 Reasons Pfizer Should Buy Celgene in 2018
You might think it's a crazy idea. Maybe it is a crazy idea. But sometimes crazy ideas are the ones that wind up being the best. So here it is: Pfizer (NYSE: PFE) should buy Celgene (NASDAQ: CELG)....
3 Highest Growth Stocks in the Market Today
I'm constantly scanning the market for stocks that promise hyper growth in the years ahead. One tool that I use to find these high growth companies is Finviz. With that in mind, I recently ran a....
Market-Moving News Is on Tap for Seattle Genetics
Seattle Genetics (NASDAQ: SGEN) Adcetris is already a successful drug with global sales of about $600 million, but sales could climb even higher if the Food and Drug Administration approves its....
3 Top Stocks Under $5
Although market cap is a more important metric to consider when determining the future value of a company's share price, it's not uncommon for investors to think that a lower stock price....
Will 2018 Be Johnson & Johnson's Best Year Yet?
There are still several weeks left in the year, but Johnson & Johnson (NYSE: JNJ) appears to be on course to generate its second-highest stock performance over the last decade in 2017. A....
Here's How Acadia Pharmaceuticals Crushed It in 2017
About 1 million patients in the U.S. suffer from Parkinson's disease. Unfortunately, nearly 40% of them will experience hallucinations and delusions in their daily life, which is a disease state....
Where Will Organovo Holdings, Inc. Be in 5 Years?
This has been a year Organovo Holdings Inc. (NASDAQ: ONVO) investors would like to forget. Revenue growth has come to a halt, inciting the market to lop off roughly half of the company's market....
5 Top Biotech Stocks to Buy Now
Over the last five years, biotech stocks have trounced the performance of the S&P 500. One major reason why is the number of new drugs launched by biotech companies. More diseases than ever....
Is a Dividend Cut Coming From GlaxoSmithKline plc?
One of the attractions of investing in British drugmaker GlaxoSmithKline plc (NYSE: GSK) is its generous dividend yield, which lately has hovered at just a bit less than 6%. A yield that's so far....
The FDA Ushers In a New Era in Cancer Treatment
On Thursday, Foundation Medicine (NASDAQ: FMI) won a green light for its comprehensive DNA test, FoundationOne CDx. The approval clears the way for healthcare providers to quickly determine what....
This Marijuana Stock Is Poised for a Breakout Year in 2018 -- Here's What You'll Want to Know About It
Admittedly, 2017 so far has kind of been a ho-hum year for former high-flying marijuana stock GW Pharmaceuticals (NASDAQ: GWPH). For the most part, investors have just been waiting for the next....
3 Biotech Stocks to Buy in December
Black Friday is past. So is Cyber Monday. But it's not too late to buy one of the best Christmas gifts of all -- biotech stocks. Even if your family and friends might prefer other kinds of....
Better Buy: Pfizer Inc. vs. Johnson & Johnson
With only one month remaining in 2017, it's pretty clear which big pharma stock has been the better pick this year between Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ). J&J's share....
Where Will Novavax, Inc. Be in 5 Years?
Prediction is very difficult, especially if it's about the future.I've always liked that quote from Nobel prize-winning physicist Niels Bohr. And it's 100% correct, of course. But attempting to....
Why 2017 Was a Year to Remember for Exact Sciences Corporation
Any year that a stock goes up 40% would count as a memorable year. But what about a year where a stock soars nearly 340%? That's what has happened for Exact Sciences Corporation (NASDAQ: EXAS) in....
Here's Why Sangamo Therapeutics Rose as Much as 14.9% Thursday
Shares of biopharma Sangamo Therapeutics (NASDAQ: SGMO) rose nearly 15% today after the company received favorable coverage in multiple media outlets. Biotech thought leaders STAT Plus and Genetic....
Gilead Sciences Stock Upgraded: This Is the Power of Free
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....